Rheumnow Podcast

ACR 2025 Daily Podcasts Day2c

NSAID Addition Helps the Spine but not the Hips 

Durability and Safety of Bimekizumab 

Progressive BiTE in SLE 2 

Hydroxychloroquine Reduces Autoantibody Levels 

When the Back Hurts: uncovering BASDAI drivers in PsA 

The Upper Hand in PsA? Not the Dominant One 

Airway Disease in GPA 

Wired for Success: Vagal Nerve Therapy in RA 

GLP-1 in Knee Osteoarthritis 

Disparities in Physical Function in SLE 

ACR 2025 Daily Podcasts Day2b

Putting Steroid Tapering into Practice in SLE 

Tocilizumab Beats Methotrexate in GCA 

GLP-1 Receptor Agonists in PsA: Mortality and MACE

Safety of CAR-T 

ILD in Patients with Connective Tissue Disease 

SLGT-2 and GLP-1 in RA: More than Weight Loss 

PsA Predictors 

Ianalumab: Breakthrough Therapy in Sjogren's

ACR 2025 Daily Podcasts Day2a

Off the Shelf: CAR-T 

Combining CAR-T with CAR-Treg All in One 

Tapering in SELECT GCA: Steroids are the Problem 

Diagnostic Delays in PsA: A Radiographic Perspective 

Late-Breaking Trials in axSpA and PsA 

New Approaches to Therapy in PsA 

PRED-SAFE: Chronic Prednisone Use 

PsA and Brain Fog 

CAR-T Therapy: Where is it Heading? 

Day 2 Recap- ACR Convergence 2025 Highlights

Join RheumNow Faculty Drs. David Liew, Antoni Chan,  Mrinalini Dey, and Jack Cush as they discuss highlights and key takeaways from the Day 2 Recap on Monday, October 27th, at the 2025 ACR Convergence meeting in Chicago.

ACR 2025 Daily Podcasts Day1c

A Nose for Vasculitis: ENT Manifestations in ANCA-Associated Disease 

Tofacitinib in AxSpA in Developing Countries 

Specialized Biomarkers in PsA 

B Cell Depletion: Check the Lymph Node 

GLP-1 and SGLT-2: Treatments Too Good to Ignore? 

Nerandomilast for ILD 

PsA: Impact of Sex 

Cellular Biomarkers of Rheumatoid Arthritis 

Using AI and LLMs in Qualitative Data 

Belimumab Before or After Immunosuppressant 

Do Patients with Rheumatic Diseases 'Weather' the Storm? 

AI in Fellow Recruitment: A New Dawn in Medical Education? 

ACR 2025 Daily Podcasts Day1b

AI Scribes Found their Favorite Doctors 

Hospitalization in Stills: Is it "Still" an Infection?

Upadacitinib is a Double Edged Vascular Sword in GCA 

Rheumatoid Arthritis: Inject the Steroids

Catching AxSpA Early: Closing the Diagnostic Gap 

Is Low Disease Activity Low Enough? 

Early Peripheral SpA: Is it okay to stop treatment sometimes?

Difficult to Manage axSpA

ACR 2025 Daily Podcasts Day1a

STOP RA Cellular & Serologic Predictors

Is AI Smarter than a Doctor?

Lung Disease in ANCA-associated Vasculitis 

Older Adults Underrepresented in RCTs 

Next Generation T-Cell Engager: The Future

Lupus in Focus: 2025 ACR Treatment Guidelines for SLE 

Psoriatic Arthritis Imaging 

 

ACR2025 Day 1 RECAP

Big takeaways, standout moments, and what set the tone for this year’s conference. We break down the key insights, early trends, and conversations shaping Day 1.

Pre-ACR25 (10.24.2025)

Dr. Jack Cush reviews the news and info reports the day before ACR 2025.

DERM on RheumNow (October 2025)

DERM on RheumNow PODCAST (October 2025)
Skin important Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. 
SHOW NOTES
1. Skin Biopsies to Predict Scleroderma Outcomes? 
2. Fibromyalgia in PsO & PsA is linked to greater treatment complexity and shorter biologic therapy survival. Retro matched 1:4 cohort study 61K PsO& 244K controls. FM prevalence 3.3% (OR 1.45). In PsA w/ FM, req more biologics w/ decr biologic survival (6 vs 10yrs) w/ incr switching (HR 1.82) https://buff.ly/TCc6Kc8
3. Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis  https://rheumnow.com/news/guselkumab-fda-approved-pediatric-psoriasis-and-psoriatic-arthritis   
4. Sonelokimab (SLK) is a nanobody that inhibits IL-17 A&F. Phase 2 ARGO trial 207 active PsA pts Rx w/ SLK 120-mg or 60-mg q4wks or PBO or adalimumab. ACR50 at wk 12 was 60-mg WI=46%; 120-mg WI=46%; PBO 20%. PASI90: 60mg 77% vs 120mg 59% vs PBO 15% https://t.co/ra0NqvUEru https://t.co/FXT6kkXUzH  
5. Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition time (~13 yrs) from PsO-to-PsA. Factors assoc w/ prolonged interval included Depression, fatigue, scalp PsO(OR 7), nail PsO (3.2), +Fhx & enthesitis ever (OR 2) https://t.co/wqtSbeQ2vz
6. Mediterranean Diet Efficacy in Psoriasis  
7. Gender Complexities in Psoriatic Arthritis Treatment Outcomes